

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
Sheet	1	of	1
		Application Number	09/868,501
		Filing Date	September 26, 2001
		First Named Inventor	Daniel G. CHAIN
		Group Art Unit	11014
		Examiner Name	SPIVACK
		Attorney Docket Number	CHAIN-4A

RECEIVED

NOV 16 2007
TECH CENTER 1600/2000

Examiner
Signature

P. Spivack

Date
Considered

4/27/04

*** EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

O I P E SCITI
M A R 1 0 2004
P A T E N T

PTO/SB/08a (06-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	09/868,501
Filing Date	September 26, 2001
First Named Inventor	Daniel G. CHAIN
Group Art Unit	1614
Examiner Name	SPIVACK
Attorney Docket Number	CHAIN=4A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
PS	DA	US-6,028,088	02-22-2000	Pershadsingh et al	
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
PS	DB	WO 99/16758 A1	04-08-1999	Reddy Research Found.		
PS	DC	WO 99/20614 A1	04-29-1999	Ready Res Found & Reddy-Cheminor, Inc.		
PS	DD	WO 99/38850 A1	08-0519-99	Reddy Research Found.		
PS	DE	WO 00/23407 A2	04-27-2000	Glaxo Group Ltd & U So Car		
PS	DF	WO 00/23415 A1	04-27-2000	Novo Nordisk & Reddy Res		
PS	DG	WO 00/23416 A1	04-27-2000	Novo Nordisk & Reddy Res		
PS	DH	WO 00/23417 A1	04-27-2000	Novo Nordisk & Reddy Res		
PS	DI	WO 00/23445 A1	04-27-2000	Novo Nordisk & Reddy Res		
PS	DJ	WO 00/23451 A1	04-27-2000	Novo Nordisk & Reddy Res		
PS	DK	WO 00/32180 A1	06-08-2000	Case Western Reserve Un		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PS	DL	COMBS et al, "Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β -Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPAR γ Agonists", <i>J Neurosci</i> 20(2):558-567 (2000)	

Examiner
Signature

P. Spivack

Date
Considered

4/27/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 4

Complete if Known

Application Number	09/868,501
Filing Date	9/26/01
First Named Inventor	Daniel G. CHAIN
Group Art Unit	1614
Examiner Name	SPINWACK
Attorney Docket Number	CHAIN=4A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PS	AA	3,929,813		Higuchi et al	12-30-1975	
PS	AB	3,962,447		Higuchi et al	06-08-1976	
PS	AC	4,340,603		Bodor et al	07-20-1982	
PS	AD	4,479,932		Bodor	10-30-1984	
PS	AE	4,540,564		Bodor	09-10-1985	
PS	AF	4,771,059		Bodor	09-13-1988	
PS	AG	4,888,427		Bodor	12-19-1989	
PS	AH	5,039,794		Wier et al	08-13-1991	
PS	AJ	5,082,853		Bodor	01-21-1992	
PS	AJ	5,166,320		Wu et al	11-24-1992	
PS	AK	5,296,483		Bodor	03-22-1994	
PS	AL	5,389,623		Bodor	02-14-1995	
PS	AM	5,457,109		Antonucci et al	10-10-1995	
PS	AN	5,478,852		Olafsky et al	12-26-1995	
PS	AO	5,525,727		Bodor	06-11-1996	
PS	AP	5,556,843		Romeo et al	09-17-1996	
PS	AQ	5,602,133		Antonucci et al	02-11-1997	
PS	AR	5,624,894		Bodor	04-29-1997	
PS	AS	5,629,319		Luo et al	05-13-1997	
PS	AT	5,629,322		Guthikonda et al	05-13-1997	
PS	AU	5,641,796		Dominiani et al	06-24-1997	
PS	AV	5,646,169		Hindley et al	07-08-1997	
PS	AW	5,668,117		Shapiro	09-16-1997	
PS	AX	5,674,900		Ubillas et al	10-07-1997	
PS	AY	5,674,980		Frankel et al	10-07-1997	
PS	AZ	5,691,386		Inman et al	11-25-1997	
PS	BA	5,693,614		Torii et al	12-02-1997	
PS	BB	5,700,820		Vyas et al	12-23-1997	
PS	BC	5,708,012		Olefsky	01-13-1998	
PS	BD	5,710,153		Ohmoto et al	01-20-1998	
PS	BE	5,747,527		Inman et al	05-05-1998	
PS	BF	5,756,525		Hindley et al	06-26-1998	
PS	BG	5,962,004		Jannella	10-05-1999	

Examiner Signature

P. Spinwack

Date Considered

4/27/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

4

Complete If Known

Application Number	09/868,501
Filing Date	
First Named Inventor	Daniel G. CHAIN
Group Art Unit	1614
Examiner Name	SPINACK
Attorney Docket Number	CHAIN=4A

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	09/868,501
Filing Date	9/26/01
First Named Inventor	Daniel G. CHAIN
Group Art Unit	164
Examiner Name	SPINACK
Attorney Docket Number	CHAIN=4A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BS	BO	BUCKLE et al, "Non Thiazolidinedione Antihyperglycaemic Agents. 1: α -Heteroatom Substituted β -Phenylpropanolic Acids", <i>Biorg & Med Chem Letter</i> 6(17):2121-2126 (1996) .	
PS	BP	CANTELLO et al, "[omega-(Heterocyclamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents", <i>J Med Chem</i> 37(23):3977-3985 (1994) .	
PS	BQ	CLARKE et al, "Insulin binds to specific receptors and stimulates 2-deoxy-D-glucose uptake in cultured glial cells from rat brain", <i>J Biol Chem</i> 259(19):11672-11675 (1984) .	
PS	BR	CULLINGFORD et al, "Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system", <i>J Neurochem</i> 70(4):1366-1375 (1998) .	
PS	BS	DIENEL et al, "Comparison of rates of local cerebral glucose utilization determined with deoxy[1-14C]glucose and deoxy[6-14C]glucose", <i>J Neurochem</i> 59(4):1430-1436 (1992) .	
BS	BT	DORÉ et al, "Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]Insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats", <i>Neuroscience</i> 80(4):1033-1040 (1997) .	
PS	BU	DOYLE et al, "Four-day hyperinsulinemia in euglycemic conditions alters local cerebral glucose utilization in specific brain nuclei of freely moving rats", <i>Brain Res</i> 684(1):47-55 (1995) .	
PS	BV	DUELLI et al, "Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats", <i>Int J Dev Neurosci</i> 12(8):737-743 (1994) .	
PS	BW	GRANNEMAN et al, "Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes", <i>J Neurosci Res</i> 51(5):563-573 (1998) .	
BS	BX	HASSELBALCH et al, "No Effect of Insulin on Glucose Blood-Brain Barrier Transport and Cerebral Metabolism in Humans", <i>Diabetes</i> 48:1915-1921 (1999) .	
PS	BY	HOYER et al, "Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptor", <i>Ann N Y Acad Sci</i> 777:374379 (1996) .	
PS	BZ	KITAMURA et al, "Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains", <i>Biochem Biophys Res Commun</i> 254(3):582-586 (1999) .	

Examiner Signature

Philip Spivack

Date Considered

4/27/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	09/868,501
Filing Date	9/26/01
First Named Inventor	Daniel G. CHAIN
Group Art Unit	1614
Examiner Name	SPNACK
Attorney Docket Number	CHAIN=4A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PS	CA	KITAMURA et al, "Activators of peroxisome proliferator-activated receptor-gamma (PPAR γ) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells", <u>Neurosci Lett</u> 262(2):129-132 (1999).	
PS	CB	KUMAGAI, "Glucose Transport in Brain and Retina: Implications in the Management and Complications of Diabetes", <u>Diabetes metab Res Rev</u> 15(4):261-273 (1999).	
PS	CC	MUKHERJEE et al, "Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists", <u>Nature</u> 386(6623):407-410 (1997).	
PS	CD	NAKAYAMA et al, "Effect of TAK-147, a novel AChE inhibitor, on cerebral energy metabolism", <u>Neurobiol Aging</u> 17(6):849-857 (1996).	
PS	CE	NEUWELT et al, "Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors", <u>Ed Proc</u> 43(2):214-219 (1984).	
PS	CF	PARDRIDGE, "Receptor-mediated peptide transport through the blood-brain barrier", <u>Endocr Rev</u> 7(3):314-330. Review (1986).	
PS	CG	PETROVA et al, "Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2", <u>Proc Natl Acad Sci USA</u> 96(8):4668-4673 (1999).	
PS	CH	POPLACK et al, "Pharmacology of Antineoplastic Agents in Cerebrospinal Fluid" in <u>Neurobiology of Cerebrospinal Fluid</u> , J.H. Wood (Ed). Plenum Press (New York, 1981), pp. 561-578.	
PS	CI	PROKAI et al, "Chemical Delivery System to Transport a Pyroglutamyl Peptide Amide to the Central Nervous System", <u>J Am Chem Soc</u> 116:2643-2644 (1994).	
PS	CJ	TSUZUKI et al, "Adamantane as a brain-directed drug carrier for poorly absorbed drug: antinociceptive effects of [D-Ala2]Leu-enkephalin derivatives conjugated with the 1-adamantane moiety", <u>Biochem Pharmacol</u> 41(4):R5-8 (1991).	

Examiner
Signature

P. SPNACK

Date
Considered

4/27/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.